By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Metamark Genetics said yesterday that it has signed a research and licensing deal with Janssen Biotech on identifying and validating prognostic markers for cancer.

The firms intend to validate several of Metamark's Prognostic Determinants, which are genes that are believed to play a causal role in promoting tumor progression and metastases. Cambridge, Mass.-based Metamark makes MetamarkDx Prognostic Assays based on the Prognostic Determinants technology.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Technology Review reports that researchers in the US have used CRISPR to modify a number of human embryos.

Plant researchers plan to sequence some 10,000 samples that represent the major plant clades, ScienceInsider reports.

By introducing genes from butterfly peas and Canterbury bells, researchers in Japan have developed a blue chrysanthemum, according to NPR.

In Nature this week: a Danish reference genome, and more.